Probucol, sold under the trade name Lorelco among others, is an anti-hyperlipidemicdrug[1] initially developed for the treatment of coronary artery disease. Clinical use was discontinued in some countries after it was found that the drug may have the undesired effect of lowering HDL in patients with a previous history of heart disease.[2][3] It may also cause QT interval prolongation.[3][4]
Probucol has also been shown to inhibit ABCA1-dependent cholesterol transport,[7] which may contribute to its known effect of lowering HDL.[8]
Researchedit
Probucol has been found to have antioxidant and anti-inflammatory properties via several different mechanisms.[9] These properties have led to research into the drug's potential capacity to treat sensorineural hearing loss related to oxidative stress,[9][10] as well as formulations to improve the delivery of the drug into the ear.[10]
After promising test results in mouse models, probucol is under study at Weston Brain Institute of McGill University as a possible aid in delaying the onset of Alzheimer's disease.[citation needed]
Referencesedit
^Yamamoto A (11 December 2008). "A Unique Antilipidemic Drug - Probucol". Journal of Atherosclerosis and Thrombosis. 15 (6): 304–5. doi:10.5551/jat.E621. PMID 19075491. Retrieved 2020-01-29.
^Yamashita S, Masuda D, Matsuzawa Y (August 2015). "Did we abandon probucol too soon?". Current Opinion in Lipidology. 26 (4): 304–16. doi:10.1097/MOL.0000000000000199. PMID 26125504. Probucol has been used as a lipid-lowering drug for a long time especially in Japan, although Western countries quitted its use because of the reduction in serum HDL-cholesterol (HDL-C).
^ abYamashita S, Matsuzawa Y (November 2009). "Where are we with probucol: a new life for an old drug?". Atherosclerosis. 207 (1): 16–23. doi:10.1016/j.atherosclerosis.2009.04.002. PMID 19457483.
^Mamoshina P, Rodriguez B, Bueno-Orovio A (March 2021). "Toward a broader view of mechanisms of drug cardiotoxicity". Cell Reports. 2 (3): 100216. doi:10.1016/j.xcrm.2021.100216. PMC7974548. PMID 33763655.
^Yamashita S, Masuda D, Matsuzawa Y (February 2021). "New Horizons for Probucol, an Old, Mysterious Drug". Journal of Atherosclerosis and Thrombosis. 28 (2): 100–102. doi:10.5551/jat.ED132. PMC7957029. PMID 32507832. Probucol was developed as an anti-oxidative compound to prevent the degradation of tire rubber and later applied to reduce serum LDL-C levels in patients with hypercholesterolemia.
^Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH (28 October 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol. 24 (12): 2345–50. doi:10.1161/01.ATV.0000148706.15947.8a. PMID 15514211.
^Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Katsuyuki N, Okazaki M, Okada M (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis. 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878. Retrieved 2020-01-29.
^ abChester J, Johnston E, Walker D, Jones M, Ionescu CM, Wagle SR, Kovacevic B, Brown D, Mikov M, Mooranian A, Al-Salami H (July 2021). "A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology". Pharmaceutics. 13 (7): 1041. doi:10.3390/pharmaceutics13071041. PMC8309044. PMID 34371732.
^ abWagle SR, Ionescu CM, Kovacevic B, Jones M, Foster T, Lim P, Lewkowicz M, Ðanić M, Mikov M, Mooranian A, Al-Salami H (May 2023). "Pharmaceutical characterization of probucol bile acid-lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies". Nanomedicine. 18 (12): 923–940. doi:10.2217/nnm-2023-0092. PMID 37529927.
January 01, 1970
probucol, sold, under, trade, name, lorelco, among, others, anti, hyperlipidemic, drug, initially, developed, treatment, coronary, artery, disease, clinical, discontinued, some, countries, after, found, that, drug, have, undesired, effect, lowering, patients, . Probucol sold under the trade name Lorelco among others is an anti hyperlipidemic drug 1 initially developed for the treatment of coronary artery disease Clinical use was discontinued in some countries after it was found that the drug may have the undesired effect of lowering HDL in patients with a previous history of heart disease 2 3 It may also cause QT interval prolongation 3 4 ProbucolClinical dataPronunciation ˈ p r oʊ b j u k ɒ l PROH bew kolTrade namesLorelcoOther names2 6 di tert butyl 4 2 3 5 di tert butyl 4 hydroxyphenyl sulfanyl propan 2 yl sulfanyl phenolAHFS Drugs comMicromedex Detailed Consumer InformationMedlinePlusa611037ATC codeC10AX02 WHO IdentifiersIUPAC name 4 4 Propane 2 2 diylbis thio bis 2 6 di tert butylphenol CAS Number23288 49 5 YPubChem CID4912IUPHAR BPS7277DrugBankDB01599 YChemSpider4743 YUNIIP3CTH044XJKEGGD00476 YChEBICHEBI 8427 NChEMBLChEMBL608 YCompTox Dashboard EPA DTXSID2045440ECHA InfoCard100 041 404Chemical and physical dataFormulaC 31H 48O 2S 2Molar mass516 84 g mol 13D model JSmol Interactive imageSMILES S c1cc c O c c1 C C C C C C C C C Sc2cc c O c c2 C C C C C C C C C CInChI InChI 1S C31H48O2S2 c1 27 2 3 21 15 19 16 22 25 21 32 28 4 5 6 34 31 13 14 35 20 17 23 29 7 8 9 26 33 24 18 20 30 10 11 12 h15 18 32 33H 1 14H3 YKey FYPMFJGVHOHGLL UHFFFAOYSA N Y N Y what is this verify Probucol was originally developed as an industrial antioxidant added to tires to maximize their longevity 5 Mechanism of action editProbucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism Additionally probucol may inhibit cholesterol synthesis and delay cholesterol absorption 6 Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs this slows the formation of foam cells which form atherosclerotic plaques Probucol has also been shown to inhibit ABCA1 dependent cholesterol transport 7 which may contribute to its known effect of lowering HDL 8 Research editProbucol has been found to have antioxidant and anti inflammatory properties via several different mechanisms 9 These properties have led to research into the drug s potential capacity to treat sensorineural hearing loss related to oxidative stress 9 10 as well as formulations to improve the delivery of the drug into the ear 10 After promising test results in mouse models probucol is under study at Weston Brain Institute of McGill University as a possible aid in delaying the onset of Alzheimer s disease citation needed References edit Yamamoto A 11 December 2008 A Unique Antilipidemic Drug Probucol Journal of Atherosclerosis and Thrombosis 15 6 304 5 doi 10 5551 jat E621 PMID 19075491 Retrieved 2020 01 29 Yamashita S Masuda D Matsuzawa Y August 2015 Did we abandon probucol too soon Current Opinion in Lipidology 26 4 304 16 doi 10 1097 MOL 0000000000000199 PMID 26125504 Probucol has been used as a lipid lowering drug for a long time especially in Japan although Western countries quitted its use because of the reduction in serum HDL cholesterol HDL C a b Yamashita S Matsuzawa Y November 2009 Where are we with probucol a new life for an old drug Atherosclerosis 207 1 16 23 doi 10 1016 j atherosclerosis 2009 04 002 PMID 19457483 Mamoshina P Rodriguez B Bueno Orovio A March 2021 Toward a broader view of mechanisms of drug cardiotoxicity Cell Reports 2 3 100216 doi 10 1016 j xcrm 2021 100216 PMC 7974548 PMID 33763655 Yamashita S Masuda D Matsuzawa Y February 2021 New Horizons for Probucol an Old Mysterious Drug Journal of Atherosclerosis and Thrombosis 28 2 100 102 doi 10 5551 jat ED132 PMC 7957029 PMID 32507832 Probucol was developed as an anti oxidative compound to prevent the degradation of tire rubber and later applied to reduce serum LDL C levels in patients with hypercholesterolemia Probucol Systemic Drugs com 1998 08 24 Retrieved 2020 01 29 Favari E Zanotti I Zimetti F Ronda N Bernini F Rothblat GH 28 October 2004 Probucol inhibits ABCA1 mediated cellular lipid efflux Arterioscler Thromb Vasc Biol 24 12 2345 50 doi 10 1161 01 ATV 0000148706 15947 8a PMID 15514211 Miida T Seino U Miyazaki O Hanyu O Hirayama S Saito T Ishikawa Y Akamatsu S Nakano T Katsuyuki N Okazaki M Okada M October 2008 Probucol markedly reduces HDL phospholipids and elevated prebeta1 HDL without delayed conversion into alpha migrating HDL putative role of angiopoietin like protein 3 in probucol induced HDL remodeling Atherosclerosis 200 2 329 35 doi 10 1016 j atherosclerosis 2007 12 031 PMID 18279878 Retrieved 2020 01 29 a b Chester J Johnston E Walker D Jones M Ionescu CM Wagle SR Kovacevic B Brown D Mikov M Mooranian A Al Salami H July 2021 A Review on Recent Advancement on Age Related Hearing Loss The Applications of Nanotechnology Drug Pharmacology and Biotechnology Pharmaceutics 13 7 1041 doi 10 3390 pharmaceutics13071041 PMC 8309044 PMID 34371732 a b Wagle SR Ionescu CM Kovacevic B Jones M Foster T Lim P Lewkowicz M Danic M Mikov M Mooranian A Al Salami H May 2023 Pharmaceutical characterization of probucol bile acid lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies Nanomedicine 18 12 923 940 doi 10 2217 nnm 2023 0092 PMID 37529927 Retrieved from https en wikipedia org w index php title Probucol amp oldid 1193107018, wikipedia, wiki, book, books, library,
